Stockscreener 앱 받기
35.57
11.86%
3.77
시간 외 거래:
36.27
0.70
+1.97%
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Dianthus Therapeutics stock hits 52-week high at 34.74 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - Yahoo Finance
Best data tools to analyze Dianthus Therapeutics Inc. stockJuly 2025 Decliners & Stepwise Swing Trade Plans - Newser
Analyzing recovery setups for Dianthus Therapeutics Inc. investorsWeekly Market Outlook & Entry Point Confirmation Signals - Newser
Using RSI to spot recovery in Dianthus Therapeutics Inc.July 2025 Closing Moves & Low Risk Investment Opportunities - Newser
Using data filters to optimize entry into Dianthus Therapeutics Inc.2025 Market Sentiment & Breakout Confirmation Trade Signals - Newser
Published on: 2025-09-09 04:51:10 - Newser
How hedge fund analytics apply to Dianthus Therapeutics Inc. stockTreasury Yields & Proven Capital Preservation Tips - Newser
Price action breakdown for Dianthus Therapeutics Inc.July 2025 Review & Technical Pattern Recognition Alerts - Newser
Technical signs of recovery in Dianthus Therapeutics Inc.Trade Volume Report & Real-Time Buy Zone Alerts - Newser
Transcript : Dianthus Therapeutics, Inc.Special Call - MarketScreener
Visual analytics tools that track Dianthus Therapeutics Inc. performanceJuly 2025 Reactions & Short-Term High Return Strategies - Newser
What momentum shifts mean for Dianthus Therapeutics Inc.2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
What data driven models say about Dianthus Therapeutics Inc.’s futurePortfolio Update Report & Precise Buy Zone Identification - Newser
Real time scanner hits for Dianthus Therapeutics Inc. explainedJuly 2025 Decliners & Daily Entry Point Alerts - Newser
Leading vs lagging indicators on Dianthus Therapeutics Inc. performanceDip Buying & Daily Price Action Insights - Newser
How to recover losses in Dianthus Therapeutics Inc. stockMarket Activity Report & Real-Time Volume Spike Alerts - Newser
Dianthus Sees Best-In-Class Potential For Claseprubart In Crowded gMG Market - insights.citeline.com
Dianthus Therapeutics launches $150 million public stock offering By Investing.com - Investing.com Canada
Dianthus Therapeutics launches $150 million public stock offering - Investing.com India
Dianthus Therapeutics Launches $150 Million Public Offering - MarketScreener
Dianthus Therapeutics launches $150 mln equity offering after shares surge - TradingView
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering - The Manila Times
$150 Million Stock Offering: Biotech Dianthus Therapeutics Raises Funds for Autoimmune Drug Development - Stock Titan
Guggenheim raises Dianthus Therapeutics stock price target to $100 on gMG data - Investing.com Canada
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again - inkl
Dianthus’ selective complement inhibitor yields Phase 2 success in myasthenia gravis - Endpoints News
Does Dianthus Therapeutics Inc. stock benefit from AI growthJuly 2025 Spike Watch & AI Enhanced Trading Signals - beatles.ru
Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline - Benzinga
Evercore ISI Adjusts Dianthus Therapeutics Price Target to $72 From $50, Maintains Outperform Rating - MarketScreener
Dianthus Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Dianthus Therapeutics stock soars after positive Phase 2 gMG trial data - Investing.com Canada
Does Dianthus Therapeutics Inc. show high probability of rebound2025 Technical Patterns & Safe Entry Momentum Stock Tips - Newser
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile - The Manila Times
Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan
Ally Bridge Group NY LLC Trims Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Visual trend scoring systems applied to Dianthus Therapeutics Inc.Index Update & Risk Controlled Daily Trade Plans - Newser
Will Dianthus Therapeutics Inc. stock go up soonJuly 2025 Patterns & Expert Curated Trade Setups - Newser
Dianthus Therapeutics Inc. stock trend forecastChart Signals & Weekly Top Stock Performers List - Newser
Applying Elliott Wave Theory to Dianthus Therapeutics Inc.July 2025 Volume & Low Drawdown Investment Ideas - Newser
Backtesting results for Dianthus Therapeutics Inc. trading strategiesJuly 2025 Rallies & AI Powered Market Entry Strategies - Newser
Heatmap analysis for Dianthus Therapeutics Inc. and competitors2025 Top Gainers & Step-by-Step Trade Execution Guides - Newser
Vestal Point Capital LP Grows Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - The Manila Times
Dianthus Therapeutics Announces Conference Call to Discuss Phase 2 MaGic Trial Results for Claseprubart in Generalized Myasthenia Gravis - Quiver Quantitative
Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart - Stock Titan
RA Capital Management L.P. Boosts Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Momentum Indicator Shows Bearish Divergence in Dianthus Therapeutics Inc.Quarterly Earnings Report & Free Real-Time Market Sentiment Alerts - beatles.ru
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Combining machine learning predictions for Dianthus Therapeutics Inc.July 2025 Rallies & Long Hold Capital Preservation Plans - Newser
Is this a good reentry point in Dianthus Therapeutics Inc.2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
Is it too late to sell Dianthus Therapeutics Inc.Weekly Stock Recap & Stepwise Trade Signal Guides - Newser
1.96%
1.11%
자본화:
|
볼륨(24시간):